TPIA:OTC-Mycotopia Therapies Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.04

Change

0.00 (0.00)%

Market Cap

USD 0.60M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

-5.67 (-3.93%)

USD 649.39B
CMXHF CSL Limited

+1.00 (+0.53%)

USD 94.38B
CSLLY CSL Ltd

+0.48 (+0.49%)

USD 92.66B
UCBJF UCB SA

N/A

USD 28.35B
UCBJY UCB SA ADR

+0.41 (+0.56%)

USD 27.94B
ARGNF argenx SE

N/A

USD 23.04B
GNMSF Genmab A/S

-1.70 (-0.66%)

USD 16.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B
IVBIY IVBIY

N/A

USD 6.79B

ETFs Containing TPIA

IDX VanEck Indonesia Index ET.. 5.15 % 0.57 %

+0.21 (+3.33%)

USD 0.03B
H4ZT:F HSBC ETFs Public Limited .. 3.74 % 0.00 %

+1.84 (+3.33%)

USD 0.10B
H4ZT:XETRA HSBC MSCI Indonesia UCITS.. 3.74 % 0.00 %

+1.82 (+3.33%)

USD 0.10B
HIDR:SW HSBC MSCI Indonesia UCITS.. 3.74 % 0.00 %

+2.24 (+3.33%)

USD 0.08B
HIDD:LSE HSBC ETFs Public Limited .. 3.59 % 0.00 %

+1.87 (+3.33%)

USD 0.08B
HIDR:LSE HSBC ETFs Public Limited .. 3.59 % 0.00 %

+172.50 (+3.33%)

USD 0.08B
EIDO iShares MSCI Indonesia ET.. 2.51 % 0.59 %

+0.47 (+3.33%)

USD 0.32B
OBOR KraneShares MSCI One Belt.. 1.83 % 0.79 %

-0.10 (3.33%)

USD 3.25M
BLES Inspire Global Hope ETF 0.00 % 0.62 %

-0.10 (3.33%)

USD 0.11B
WWJD Inspire International ESG.. 0.00 % 0.00 %

-0.27 (3.33%)

USD 0.29B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 150.00% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.00% 93% A 95% A
Trailing 12 Months  
Capital Gain 21.21% 78% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.21% 78% C+ 75% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -48.79% 6% D- 2% F
Dividend Return -48.79% 7% C- 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.57% 63% D 50% F
Risk Adjusted Return -98.43% 13% F 5% F
Market Capitalization 0.60M 24% F 16% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector